Pasar al contenido principal

DISECCIONANDO EL PAPEL DEL ESPACIO PERIVASCULAR CEREBRAL Y EL SISTEMA GLINFATICO EN LA DEMENCIA DE CAUSA VASCULAR

PID2022-140616OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Effect of lipotoxic hepatocyte-derived extracellular vesicles in pancreas inflammation: essential role of macrophage TLR4 in beta cell functionality

  • Alén, Rosa
  • García-Martínez, Irma
  • Cobo-Vuilleumier, Nadia
  • Fernández-Millán, Elisa
  • Gallardo-Villanueva, Paula
  • Ferreira, Vítor
  • Izquierdo, Manuel
  • Moro, María Ángeles
  • Lizasoain, Ignacio
  • Nieto, Natalia
  • Gauthier, Benoit R.
  • Valverde, Ángela M.
[Aims/hypothesis]: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common feature of obesity and type 2 diabetes. Under lipotoxic stress, hepatocytes release small extracellular vesicles (sEVs) which act locally and contribute to MASLD progression, but their role in beta cell function and development of type 2 diabetes remains largely unexplored. We aimed to examine whether hepatocyte-derived sEVs (Hep-sEVs) under lipotoxic conditions impact on liver and pancreas inflammation and subsequent effects on beta cell function., [Methods]: Primary mouse hepatocytes and Huh7 human hepatocytes were treated with palmitic acid and Hep-sEVs were purified from the culture medium by differential ultracentrifugation. In vitro and in vivo approaches were used to decipher the role of Hep-sEVs in liver and pancreas inflammation and beta cell dysfunction in mouse and human pancreatic islets. The contribution of the Toll-like receptor 4 (TLR4) to Hep-sEV-mediated effects was investigated in pancreatic islets from myeloid-specific TLR4-deficient mice., [Results]: Lipotoxic Hep-sEVs targeted pancreatic islet macrophages and induced TLR4-mediated inflammation. The subsequent inflammatory response downregulated beta cell identity genes and impaired glucose-stimulated insulin secretion in both INS-1 beta cells (p<0.05) and isolated pancreatic islets from mice (p<0.01) and humans (p<0.05). Specific deletion of TLR4 in macrophages protected pancreatic islets against inflammation and the impairment of glucose-stimulated insulin secretion induced by lipotoxic Hep-sEVs. Chronic administration of lipotoxic Hep-sEVs in lean mice induced liver and pancreas inflammation through the recruitment of immune cells. This intervention induced hepatocyte injury and fibrotic damage together with detrimental immunometabolic systemic effects. Insulin resistance in hepatocytes (p<0.01) and a compensatory insulin secretion (p<0.001) that prevented glucose intolerance were also observed in mice treated with lipotoxic Hep-sEVs., [Conclusions/interpretation]: This study has provided evidence of liver and pancreas inflammation and beta cell dysfunction induced by lipotoxic Hep-sEVs. Our data also envision TLR4-mediated signalling in islet macrophages as a key mediator of the effects of lipotoxic Hep-sEVs on beta cell function., This work was supported by grants PID2021-122766OB-I00 (AMV), PID2022-140616OB-I00 (MAM), PID2020-116134RB-I00 (EF-M), PID2021-123083NB-I00 (BRG) and RD21/0006/0001 (ISCIII) (IL) funded by MICIU/AEI/10.13039/501100011033 and, as appropriate, by “ERDF A way of making Europe”, by “ERDF/EU”, by the “European Union” or by the “European Union NextGenerationEU/PRTR”, grant EFSD/Boehringer Ingelheim European Research Programme on 'Multi-System Challenges in Diabetes' from the European Foundation for the Study of Diabetes (AMV), P2022/BMD-7227 (Comunidad de Madrid, Spain) (AMV), Fundación Ramón Areces (Spain) (AMV), Horizon-EIC-Pathfinder-Challenge-2023, grant agreement number 101162517, European Union (AMV), Breakthrough T1D (formerly known as JDRF; 3-SRA-2023-1307-S-B to BRG), CIBERdem (ISCIII, Spain) (AMV and BRG), 1R01DK134461 from the National Institute of Diabetes and Digestive and Kidney Diseases (NN) and 1I01BX005093 from the Department of Veterans Affairs (Biomedical Laboratory Research and Development). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government (NN). AMV belongs to the Spanish National Research Council (CSIC)’s Cancer and Metabolism (COMETA) Hubs and Instituto de Investigación Sanitaria La Paz (IdiPaz) (Madrid, Spain). We also acknowledge the Spanish Ministry of Economy and Competitiveness (MINECO) for the postdoctoral contract IJCI-2015-24758 to IG-M and the Spanish Ministry of Education, Culture and Sport (MECD) for the FPU17/02786 grant to RA., Peer reviewed